<DOC>
	<DOCNO>NCT00877149</DOCNO>
	<brief_summary>The purpose trial provide data absence inflammation patient liver histology long-term telbivudine treatment thus help investigator make comprehensive judgment treatment discontinuation select patient</brief_summary>
	<brief_title>Efficacy Telbivudine Treatment Long Term Absence Liver Inflammation Patients With Compensated Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Patient complete study CLDT600ACN04 study available immediately rollover study without discontinuation study drug . Patient discontinue previous CLDT600ACN04 study . Adult patient CHB ( HBeAg positive HBeAg negative ) . HBV DNA PCR undetectable recent 12 month . Pregnant breastfeeding , plan pregnant study period . Patient coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , HIV screen visit . Patient receive within past 12 month antiHBV treatment combination ( addon therapy ) switch anti HBV treatment Telbivudine investigator 's discretion . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Chronic HBV</keyword>
</DOC>